1. Sakurai H, Ishikawa H, Okumura T. Proton beam therapy in Japan: current and future status. Jpn J Clin Oncol. 2016;46(10):885-92.
2. Oshiro Y, Mizumoto M, Okumura T, Fukuda K, Fukumitsu N, Abei M, et al. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. Radiother Oncol. 2017;123(2):240-5.
3. Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, et al. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys. 2011;81(4):1039-45.
4. Kinjo N, Ikeda Y, Taguchi K, Sugimoto R, Maehara S, Tsujita E, et al. Hepatic resection of hepatocellular carcinoma after proton beam therapy: A case report. Hepatol Res. 2016;46(5):483-8.
5. Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, et al. Long- term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108(3):497-503.
6. Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005;11(10):3799-805.
7. Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol. 2018;24(28):3090-100.
8. Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2017;17(10):911-24.
9. Granovetter M. Proton radiotherapy for primary liver cancers. Lancet Oncol. 2016;17(2):e49.
10. Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol. 2009;185(12):782-8.
11. Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010;76(2):460-6.
12. Lock M, Malayeri AA, Mian OY, Mayr NA, Herman JM, Lo SS. Computed tomography imaging assessment of postexternal beam radiation changes of the liver. Future Oncol. 2016;12(23):2729-39.
13. Ahmadi T, Okumura T, Onaya H, Akine Y, Itai Y. Preservation of hypervascularity in hepatocellular carcinoma after effective proton-beam radiotherapy--CT observation. Clin Radiol. 1999;54(4):253-6.
14. Ahmadi T, Itai Y, Onaya H, Yoshioka H, Okumura T, Akine Y. CT evaluation of hepatic injury following proton beam irradiation: appearance, enhancement, and 3D size reduction pattern. J Comput Assist Tomogr. 1999;23(5):655-63.
15. Onaya H, Itai Y, Yoshioka H, Ahmadi T, Niitsu M, Okumura T, et al. Changes in the liver parenchyma after proton beam radiotherapy: evaluation with MR imaging. Magn Reson Imaging. 2000;18(6):707-14.
16. Onaya H, Itai Y, Ahmadi T, Yoshioka H, Okumura T, Akine Y, et al. Recurrent hepatocellular carcinoma versus radiation-induced hepatic injury: differential diagnosis with MR imaging. Magn Reson Imaging. 2001;19(1):41-6.
17. Takamatsu S, Yamamoto K, Maeda Y, Kawamura M, Shibata S, Sato Y, et al. Evaluation of Focal Liver Reaction after Proton Beam Therapy for Hepatocellular Carcinoma Examined Using Gd-EOB-DTPA Enhanced Hepatic Magnetic Resonance Imaging. PLoS One. 2016;11(12):e0167155.
18. Takamatsu S, Kozaka K, Kobayashi S, Yoneda N, Yoshida K, Inoue D, et al. Pathology and images of radiation-induced hepatitis: a review article. Jpn J Radiol. 2018;36(4):241-56.
19. NCCN clinical practice guidelines in oncology: hepatobiliary cancers, Version1.2019. J Natl Compr Canc Netw. 2019.
20. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43.
21. Kim TH, Park JW, Kim BH, Kim DY, Moon SH, Kim SS, et al. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2018;9(3):4034-43.
22. Fukumitsu N, Ishida M, Terunuma T, Mizumoto M, Hashimoto T, Moritake T, et al. Reproducibility of image quality for moving objects using respiratory-gated computed tomography: a study using a phantom model. J Radiat Res. 2012;53(6):945-53.
23. Murata S, Itai Y, Asato M, Kobayashi H, Nakajima K, Eguchi N, et al. Effect of temporary occlusion of the hepatic vein on dual blood in the liver: evaluation with spiral CT. Radiology. 1995;197(2):351-6.
24. Murata S, Itai Y. Hepatic arteriography in patients with hepatocellular carcinoma under balloon occlusion of a hepatic vein draining the tumor-bearing liver parenchyma: useful for arterial infusion treatment? AJR Am J Roentgenol. 1996;167(4):1063-4.
25. Sanuki-Fujimoto N, Takeda A, Ohashi T, Kunieda E, Iwabuchi S, Takatsuka K, et al. CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. Br J Radiol. 2010;83(996):1063-71.
26. Sanuki N, Takeda A, Mizuno T, Oku Y, Eriguchi T, Iwabuchi S, et al. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol. 2013;201(6):W812-20.
27. Luhr A, von Neubeck C, Pawelke J, Seidlitz A, Peitzsch C, Bentzen SM, et al. "Radiobiology of Proton Therapy": Results of an international expert workshop. Radiother Oncol. 2018;128(1):56-67.
28. Haber AH, Rothstein BE. Radiosensitivity and rate of cell division: "law of Bergonie and Tribondeau". Science. 1969;163(3873):1338-9.
29. Gomes AR, Abrantes AM, Brito AF, Laranjo M, Casalta-Lopes JE, Goncalves AC, et al. Influence of P53 on the radiotherapy response of hepatocellular carcinoma. Clin Mol Hepatol. 2015;21(3):257-67.
30. Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol. 2012;39(4):461-72.
31. Solberg TD, Nearman J, Mullins J, Li S, Baranowska-Kortylewicz J. Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(3):918-26.
32. Reed GB, Jr., Cox AJ, Jr. The human liver after radiation injury. A form of veno- occlusive disease. Am J Pathol. 1966;48(4):597-611.
33. Fajardo LF, Colby TV. Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med. 1980;104(11):584-8.
34. Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, et al. Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography. Cardiovasc Intervent Radiol. 2009;32(2):255-64.
35. Miyayama S, Matsui O, Taki K, Minami T, Ryu Y, Ito C, et al. Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization. Cardiovasc Intervent Radiol. 2006;29(1):39-48.
36. Soo CS, Chuang VP, Wallace S, Charnsangavej C, Carrasco H. Treatment of hepatic neoplasm through extrahepatic collaterals. Radiology. 1983;147(1):45-9.
37. Xia J, Ren Z, Ye S, Sharma D, Lin Z, Gan Y, et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol. 2006;59(3):407-12.
38. Charnsangavej C, Chuang VP, Wallace S, Soo CS, Bowers T. Angiographic classification of hepatic arterial collaterals. Radiology. 1982;144(3):485-94.
39. Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol. 1997;52(1):36-40.
40. Karapanayiotides T, Goulis J, Theodorou A, Anastasiou A, Georgiadis G, Ilonidis G. Lipiodol brain embolism during hepatic transcatheter arterial chemoembolization. J Neurol. 2009;256(7):1171-3.
41. Wu H, Zhao W, Zhang J, Han J, Liu S. Clinical characteristics of hepatic Arterioportal shunts associated with hepatocellular carcinoma. BMC Gastroenterol. 2018;18(1):174.
42. Senokuchi T, Baba Y, Hayashi S, Nakajo M. Embolization of hepatic arteriovenous shunt with absolute ethanol in a patient with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2011;34 Suppl 2:S154-6.
43. Hoshiai S, Mori K, Ishiguro T, Konishi T, Uchikawa Y, Fukuda K, et al. Balloon- Assisted Chemoembolization Using a Micro-Balloon Catheter Alongside a Microcatheter for a Hepatocellular Carcinoma with a Prominent Arterioportal Shunt: A Case Report. Cardiovasc Intervent Radiol. 2017;40(4):625-8.